Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05400122
Title	Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Jennifer Eva Selfridge
Indications	chronic lymphocytic leukemia acute lymphoblastic leukemia indolent plasma cell myeloma acute myeloid leukemia rectum adenocarcinoma myelodysplastic syndrome non-Hodgkin lymphoma colon adenocarcinoma chronic myeloid leukemia Hodgkin's lymphoma myeloproliferative neoplasm
Therapies	Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine
Age Groups:	senior \| adult
Covered Countries	USA